# A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

> **NCT03280030** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 67 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Midostaurin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03280030
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-06
- **Primary completion:** 2022-11-14
- **Final completion:** 2022-11-14
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03280030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03280030, "A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03280030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*